Selecting the wrong outsourcing partner rarely surfaces at the point of decision. It shows up later, when a CMC submission has to reconcile development and manufacturing data from two separate organizations under two separate quality systems, or when a site change filing delays commercial manufacturing because development and validation work was split across vendors.
Each of these partner types operates within a defined scope. That scope determines what each organization owns, where their responsibility ends, and what falls to the sponsor to manage in between. For drug delivery programs with meaningful scientific and regulatory complexity, understanding where that scope ends matters as much as understanding what it covers.
What Each Partner Type Brings to Your Program
Contract Manufacturing Organization (CMO)
A CMO’s scope begins where development ends. They receive a validated formulation, a defined manufacturing process, and the supporting documentation package, then produce the drug product at scale under GMP conditions. Their value is manufacturing capacity, operational efficiency, and regulatory compliance at the commercial stage.
Formulation science falls outside that scope. A CMO is not positioned to resolve a development problem that arrives embedded in a process package. Their function assumes the problem was solved before they were engaged.
Contract Development Organization (CDO)
A CDO operates in the earlier, more scientifically intensive stages of a program. Preformulation characterization, formulation development, excipient compatibility studies, early analytical method development, and stability testing fall within their remit, along with, in many cases, small-scale GMP manufacturing for Phase I clinical supply.
The scientific depth a CDO brings to early-stage programs is genuine. The structural limitation is commercial-scale manufacturing. Most CDOs do not maintain that capability, which means a vendor transition is built into the program from the start.
Contract Research Organization (CRO)
A CRO manages early-stage animal testing and human clinical trial execution: protocol design, site selection and management, selection of the appropriate species, patient recruitment, data management, and regulatory submission support. Their work runs parallel to manufacturing operations rather than intersecting with them.
A CRO does not perform formulation science or manufacturing, but they do coordinate with whoever does on clinical supply logistics, labeling specifications, and investigational product documentation. Sponsors sometimes conflate CRO selection with their manufacturing and development outsourcing decisions. They are distinct functions. Clinical trial execution runs in parallel with formulation and manufacturing work, not through them, and the sponsor typically manages the interface between them.
Contract Development and Manufacturing Organization (CDMO)
A CDMO integrates development and manufacturing under a single organizational structure. The formulation scientists, process development engineers, and commercial manufacturing teams operate from a shared data set throughout the program lifecycle. That continuity changes the character of scale-up, because the formulation decisions made in development are visible to the engineers scaling the process, and vice versa.
It also has direct regulatory consequences. Development and manufacturing data reside in a single quality system, which simplifies CMC documentation and reduces the surface area for FDA questions about process equivalence between development and commercial scales.
How Partner Type Fits in the Drug Development Lifecycle
Pre-Clinical and Discovery
At the pre-clinical stage, the central question is whether the molecule is a viable candidate for the intended dosage form. API characterization, solubility and permeability profiling, and early excipient screening drive that assessment.
Both a CDO and a CDMO can answer that question. The difference is that a CDMO uses the same assessment to inform downstream manufacturing strategy, which can prevent formulation choices that create scale-up complications later.
Phase I: IND-Enabling Studies and Clinical Supply
Phase I introduces GMP clinical supply manufacturing as a program requirement. A CDO that lacks in-house GMP manufacturing capability must engage a separate CMO to produce clinical supplies before formulation development is complete. That means a manufacturing organization is receiving a process whose parameters may still be in flux.
A CDMO handles IND-enabling formulation work and GMP clinical supply manufacturing within the same organizational structure, without a vendor transition at this stage. CRO engagement typically begins around Phase I as well. A CDMO with clinical supply experience understands the documentation, labeling, and timeline specifications that CROs need to manage investigational product logistics, which reduces the coordination burden the sponsor would otherwise carry.
Phase II: Process Development and Scale-Up
Phase II is where the gap between a “CDO-plus-CMO” model and a CDMO becomes most consequential. Moving a formulation from bench-scale development to pilot-scale process development requires continuity between the scientists who designed the formulation and the engineers scaling the process. When those are separate organizations, every underdocumented parameter in the process package becomes a problem that the receiving organization must resolve at a stage when the program is already under clinical pressure.
Analytical method transfer is a specific version of this risk. A CDO develops release, stability, and in-process control methods on their instrumentation and validates them against their SOPs. When those methods move to a separate CMO for commercial release testing, method transfer validation is a regulatory requirement.
When the receiving site’s equipment or process conditions require changes to the method itself, rather than straightforward adoption, revalidation is required. The distinction between method transfer and method revalidation often does not become apparent until the CMO has attempted to run the method.
READ MORE: What Pharma Companies Need to Know About Technology Transfers & How to Get Started in 2026
Phase III: Process Validation and NDA Readiness
Process validation is the central CMC deliverable ahead of NDA or BLA submission. FDA expects consecutive conformance batches to demonstrate that the commercial manufacturing process is controlled within validated parameters. When a CDO generates the development data, and a CMO executes validation, the CMC section of the submission draws on records from two separate organizations and two separate manufacturing sites.
Managing that across a submission is achievable, but it introduces regulatory overhead that is absent in a single CDMO relationship. Development data, scale-up data, and validation data within a single site quality system produce a more coherent CMC narrative and a simpler response posture when FDA questions arise regarding process continuity.
Regulatory and Analytical Ownership in Split-Vendor Programs
The regulatory burden of splitting development and manufacturing across vendors is often underestimated during program planning. Three areas carry the most consistent risk.
CMC Narrative Continuity
The CMC section of an IND or NDA documents the complete manufacturing history of the drug product from early development through clinical supply or commercial-scale production. When that history spans two organizations, the sponsor is responsible for constructing a coherent regulatory narrative across separate quality systems.
For complex dosage forms, where the FDA will scrutinize the relationship between development-scale and commercial-scale process data, the absence of a unified data set creates questions that require active management throughout the drug approval review cycle.
Manufacturing Site Change Filings
Transitioning from a CDO to a CMO after Phase II introduces a manufacturing site change that the program’s CMC documentation will have to account for.
The CMC section of an NDA is expected to present a coherent manufacturing history covering formulation development, scale-up, and process validation as a continuous narrative. When those stages occur in separate organizations under separate quality systems, that narrative doesn’t naturally exist. The sponsor has to construct it, reconciling data from two sites into a submission package that reads as if the program always had a plan.
For complex dosage forms, that gap gets scrutinized. FDA review of the relationship between development-scale and commercial-scale process data is substantive, and discontinuities between sites create questions that don’t resolve quickly. Managing those questions through the review cycle adds time the program typically doesn’t have.
READ MORE: From Stranded Program to First-in-Class Approval
Analytical Method Ownership
Methods developed by a CDO reside in their quality system, are validated on their equipment, and are documented in their calibration and performance qualification records. A CMO taking on commercial release testing must either qualify those methods on their platform or revalidate them where instrument or process differences require it. Method revalidation is time-bound work that is difficult to compress, and its full scope is often not known until the CMO has attempted the transfer.
How CDMO Capabilities Vary Across the Market
Selecting a CDMO resolves the structural risk of splitting development and manufacturing across vendors. Whether the CDMO has the depth required for the specific dosage form the program involves is a separate question, and it matters.
Generalist CDMOs develop and manufacture across a wide range of dosage forms, including solid oral, injectables, topicals, and transdermal patches, with varying depth across each. For programs where the dosage form is established and the molecule’s physicochemical profile is well characterized, a generalist CDMO can be an appropriate fit. The integration benefit holds regardless of specialization level.
The limitation of the generalist model surfaces with dosage form complexity:
- Oral thin film manufacturing requires continuous-casting infrastructure, in-process content-uniformity testing across the film surface, and format-specific analytical controls distinct from those in solid oral manufacturing. These are not capabilities that generalist CDMOs typically maintain at clinical and commercial depth.
- Transdermal and topical patch development involves characterization of adhesive systems, uniformity of coating weight, specifications for liner release force, and control of residual solvents. Each is highly formulation-specific and requires a manufacturing infrastructure built around the format.
A generalist CDMO resolves the vendor-split problem. It does not resolve the capability gap if the organization has not built the specialized infrastructure and scientific history these formats require.
When the Class of CDMO Becomes the Decision
The risks covered in the sections above apply when development and manufacturing are divided across vendors. A CDMO eliminates that structure. What it does not eliminate is the possibility that the selected CDMO lacks the format-specific depth the program requires.
For OTF and transdermal programs, that gap is practical. Continuous-casting infrastructure, adhesive-system expertise, and format-specific regulatory history are not capabilities a CDMO acquires incidentally. They reflect deliberate investment in a specific class of programs. Where that investment exists, it shows most clearly in scale-up execution and in the regulatory record on which the submission is built.
For OTF and transdermal drug delivery programs, ARx operates as that specialist partner, from early formulation development through commercial manufacturing. Connect with our team to discuss your program and kick off a feasibility assessment.